Publications by authors named "D Buonfrate"

The aim was to assess the efficacy of ivermectin moxidectin for treating infection. Ovid MEDLINE, Embase and Web of Science databases were searched for studies comparing ivermectin and moxidectin from inception to February 2024. The outcomes: elimination of infection or parasitological cure, mortality and serious adverse events.

View Article and Find Full Text PDF

Background: Strongyloidiasis is a neglected tropical disease (NTD) caused by the soil-transmitted helminth Strongyloides stercoralis, recently included in the 2030 targets of the World Health Organization for the control of STHs. Assessment of infection prevalence is fundamental for decision-making about the implementation of control programs, but diagnostic assays to be applied in such context require evaluation. Seroassays based on recombinant antigens, which could be produced in a standardized and scalable manner, are particularly appealing for use in control programs.

View Article and Find Full Text PDF

Background: Strongyloidiasis is a chronic parasitic disease that results in relevant human morbidity, caused by the nematode Strongyloides stercoralis. This nematode has a unique and complex life-cycle. There is so far no perfect test for this helminthiasis.

View Article and Find Full Text PDF
Article Synopsis
  • Strongyloidiasis is a widespread parasitic infection affecting 300-600 million people, particularly in tropical regions, and poses serious health risks, especially during immunosuppression, with high fatality rates.
  • There have been no significant global health initiatives targeting this disease until recently, when the WHO included it in their roadmap for controlling neglected tropical diseases, highlighting its importance.
  • The new WHO guidelines recommend mass drug administration of ivermectin in areas with a prevalence of over 5%, aiming for effective public health strategies to combat strongyloidiasis.
View Article and Find Full Text PDF